How many drugs treat Tenosynovitis?

Drug Landscape tracks 10 marketed treatments for Tenosynovitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/tenosynovitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Tenosynovitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tenosynovitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Tenosynovitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Voltaren	DICLOFENAC	Hisamitsu Pharmaceutical Co., Inc	Nonsteroidal Anti-inflammatory Drug	Prostaglandin G/H synthase 2	1988-01-01
Arthrotec	Diclofenac Sodium	Pfizer	diclofenac	Acid-sensing ion channel 3	1988-01-01
Decadron	dexamethasone	Generic (originally Merck)	Corticosteroid [EPC]	Annexin A1, Interleukin-4, Androgen receptor	1958-10-30
Medrol	methylprednisolone	Generic (originally Upjohn/Pfizer)	Glucocorticoid (corticosteroid)	Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor	1957-10-01
Prelone	prednisolone	Generic (originally Schering)	Glucocorticoid (corticosteroid)	Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1	1955-01-01
Solu-Cortef	hydrocortisone succinate	Pfizer	Corticosteroid	Glucocorticoid receptor	1955-01-01
Cortef	hydrocortisone	Generic (originally Merck/Upjohn)	Corticosteroid [EPC]	Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible	1952-01-01
Cortifoam	HYDROCORTISONE ACETATE	Pfizer	Corticosteroid	Corticosteroid-binding globulin	1951-01-01
Indom	Indom	University of Trieste		Aldo-keto reductase family 1 member C4, Dehydrogenase/reductase SDR family member 9, Nicotinate phosphoribosyltransferase
Cortisol	Cortisol	University of Zurich		Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 5 drugs in Tenosynovitis
Pfizer · 3 drugs in Tenosynovitis
Generic (originally Merck/Upjohn) · 1 drug in Tenosynovitis
Generic (originally Schering) · 1 drug in Tenosynovitis
Generic (originally Upjohn/Pfizer) · 1 drug in Tenosynovitis
Hannover Medical School · 1 drug in Tenosynovitis
Hisamitsu Pharmaceutical Co., Inc · 1 drug in Tenosynovitis
Leiden University Medical Center · 1 drug in Tenosynovitis
Maastricht University Medical Center · 1 drug in Tenosynovitis
University of Trieste · 1 drug in Tenosynovitis
University of Zurich · 1 drug in Tenosynovitis
Generic (originally Merck) · 1 drug in Tenosynovitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Tenosynovitis:

Cite this brief

Drug Landscape (2026). Tenosynovitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/tenosynovitis. Accessed 2026-06-10.

Tenosynovitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing